StocksMedium•5 November 2026•
1 min read
OS Therapies Requalifies Herlystic Drug Substance for Phase 3 Trials
Key Facts
1OS Therapies announced the completion of drug substance requalification used in its Phase 2b trial of OST-HER2 (Herlystic).
2The milestone allows the company to complete CMMA submissions to the U.K.'s MHRA for early commercial access and trial authorization.
OS Therapies announced the completion of drug substance requalification used in its Phase 2b trial of OST-HER2, also known as Herlystic. Newsfile Corp reported that this milestone allows the company to complete submissions to the U.K.'s MHRA for early commercial access and trial authorization.
OS Therapies closed at $1.15 on November 4, 2026, with the stock reaching a day high of $1.21 and a low of $1.11 during that session. This technical requalification ensures the drug substance meets the necessary standards for the upcoming confirmatory Phase 3 trial.